|
gptkbp:instanceOf
|
benzodiazepine
controlled substance
sedative-hypnotic drug
|
|
gptkbp:ATCCode
|
N05CA06
|
|
gptkbp:brand
|
gptkb:Seconal
gptkb:Seconal_Sodium
|
|
gptkbp:CASNumber
|
76-73-9
|
|
gptkbp:category
|
benzodiazepine
anticonvulsant
hypnotic
preanesthetic
euthanasia agent
|
|
gptkbp:chemicalFormula
|
C12H18N2O3
|
|
gptkbp:color
|
white
|
|
gptkbp:contraindication
|
porphyria
severe respiratory insufficiency
history of addiction
|
|
gptkbp:discoveredBy
|
gptkb:Donalee_L._Tabern
gptkb:Ernest_H._Volwiler
|
|
gptkbp:discoveredIn
|
1928
|
|
gptkbp:eliminationHalfLife
|
15-40 hours
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
gptkbp:form
|
crystalline powder
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
secobarbital
|
|
gptkbp:IUPACName
|
5-allyl-5-(1-methylbutyl)barbituric acid
|
|
gptkbp:legalStatus
|
gptkb:Schedule_II_controlled_substance
|
|
gptkbp:marketedAs
|
1934
|
|
gptkbp:mechanismOfAction
|
GABAA receptor positive allosteric modulator
|
|
gptkbp:medicalUse
|
seizure control
treatment of insomnia
preoperative sedation
|
|
gptkbp:meltingPoint
|
145-146°C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
226.28 g/mol
|
|
gptkbp:pregnancyCategory
|
D
|
|
gptkbp:PubChem_CID
|
CHEMBL1201192
5007
5193
DB00239
|
|
gptkbp:riskOfOverdose
|
high
|
|
gptkbp:routeOfAdministration
|
oral
rectal
|
|
gptkbp:sideEffect
|
dizziness
drowsiness
respiratory depression
dependence
|
|
gptkbp:solubility
|
slightly soluble in water
|
|
gptkbp:synonym
|
gptkb:secobarbital_sodium
quinalbarbitone
|
|
gptkbp:UNII
|
K3W5F2G96A
|
|
gptkbp:usedInAssistedSuicide
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Schedule_II_drugs
gptkb:Schedule_II_controlled_substance
|
|
gptkbp:bfsLayer
|
8
|